This article looks at what a transition to propellants with lower Global Warming Potential will involve and the lessons that can be learned from the industry’s earlier transition from CFCs to HFAs. Key issues that need to be addressed as formulators learn to work with propellants such as HFA 152a and HFO 1234ze include solubility of the active, the profile of the emitted spray, droplet size and evaporation, and electrostatic characteristics.
Aptar Pharma offers a comprehensive suite of services for those looking to accelerate their transition to low carbon MDIs including the Nanopharm SmartTrack™ platform which provides a wealth of information for formulation optimization.
Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery
This Might Also Be of Interest
Comparison of Pulmonary Deposition for Single and Multidose Dry Powder Inhalers with ...
Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions
Accelerating the development of COVID vaccines and therapeutics
Webinars, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions
Evaluating the Particle Distribution for Dry Powder Inhalers
Publications, Pharmaceutical, Innovation & Insights, Brand Differentiation, Product Solutions
Developing in vitro dissolution tests for orally inhaled drug products
Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions
